Cabozantinib S-malate Patent Expiration
Cabozantinib S-Malate is used for treating advanced renal cell carcinoma, differentiated thyroid cancer, and hepatocellular carcinoma. It was first introduced by Exelixis Inc
Cabozantinib S-malate Patents
Given below is the list of patents protecting Cabozantinib S-malate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cabometyx | US11141413 | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | Apr 17, 2037 | Exelixis Inc |
| Cabometyx | US9724342 | C-met modulator pharmaceutical compositions | Jul 09, 2033 | Exelixis Inc |
| Cabometyx | US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis Inc |
| Cabometyx | US12128039 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis Inc |
| Cometriq | US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis |
| Cometriq | US12128039 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis |
| Cometriq | US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | Feb 10, 2032 | Exelixis |
| Cabometyx | US10034873 | C-met modulator pharmaceutical compositions | Jul 18, 2031 | Exelixis Inc |
| Cabometyx | US10039757 | C-Met modulator pharmaceutical compositions | Jul 18, 2031 | Exelixis Inc |
| Cabometyx | US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | Oct 08, 2030 | Exelixis Inc |
| Cometriq | US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | Oct 08, 2030 | Exelixis |
| Cabometyx | US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cabometyx | US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cabometyx | US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis Inc |
| Cometriq | US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cometriq | US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cometriq | US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | Jan 15, 2030 | Exelixis |
| Cabometyx | US7579473 | c-Met modulators and methods of use |
Aug 14, 2026
(Expired) | Exelixis Inc |
| Cometriq | US7579473 | c-Met modulators and methods of use |
Aug 14, 2026
(Expired) | Exelixis |
| Cabometyx | US8497284 | C-met modulators and method of use |
Sep 24, 2024
(Expired) | Exelixis Inc |
Cabozantinib S-malate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cabozantinib S-malate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
